Physician profile
Robert Partovy
NPI 1063591477
$2,590.24
in general payments reported to CMS, 2019-2025
20 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $97.89 · 2021: $676 · 2022: $352 · 2023: $478 · 2024: $540 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,079.80 | 2020-2025 | Ozempic, Rybelsus |
| Amgen INC. | $272.68 | 2024-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $214.18 | 2019-2021 | |
| Abbvie INC. | $142.96 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $126.55 | 2019-2024 | |
| Glaxosmithkline, LLC. | $123.06 | 2023 | Arexvy |
| Lilly USA, LLC | $84.59 | 2022-2024 | Mounjaro, Zepbound |
| Hologic Sales and Service, LLC | $69.34 | 2019-2021 | |
| Abbott Laboratories | $62.48 | 2022-2023 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $61.73 | 2024 | Voquezna |
| Allergan, INC. | $38.70 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $34.93 | 2024 | Austedo Xr |
| Shield Therapeutics INC | $25.62 | 2023 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $24.76 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $22.92 | 2021 | |
| Neurocrine Biosciences, INC. | $21.97 | 2023 | Ingrezza |
| Astrazeneca Pharmaceuticals Lp | $20.88 | 2020 | |
| Alnylam Pharmaceuticals INC. | $16.47 | 2024 | Onpattro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Partovy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.